What is the Schizophrenia Model?

Schizophrenia is undoubtedly a debilitating disorder that affects approximately 1% of the worlds population. The disorder is categorised by ‘positive symptoms’, ‘negative symptoms’ and it's cognitive deficits.

Research into psychotic disorders such as schizophrenia involves multiple animal models as a tool for research and testing including in the pre-clinical development of drugs.

Patients with schizophrenia typically exhibit disturbances regarding information processing along with cognitive impairment. These disturbances are clinically investigated with different paradigms of auditory event related potentials (ERP) as well as by appropriate cognitive tests aligned to specific cognitive domains, recommended by MATRICS, CNTRIS and TURNS initiatives, which can be recapitulated in rodents.

Various models simulate schizophrenia defects. These models fit into four basic categories: pharmacological models, developmental models, lesion models, and genetic models. Typically, pharmacological / drug-induced models are the most commonly used.

At Transpharmation, our elegant electrophysiological approach enables detection of translational ERP endpoints such as N1 and MMN-like responses in standard and oddball paradigm stimuli in response to test compounds, benchmarked against NMDA antagonists, (ketamine, MK-801, PCP). Furthermore, our battery of rodent cognition tests provides the opportunity for assessing whether NCEs have the potential utility for treating a range of cognitive impairments associated with schizophrenia compared to atypical antipsychotics such as clozapine.

We also offer ‘classical models’ of positive symptoms, e.g amphetamine-evoked behaviour, using our advanced LABORAS home cage monitoring system.

Animals are often used as models for monitoring schizophrenia include rats, primates and mice. We primarily use mice due to our extensive experience in working with them.

sease relevant models we offer include the following:

  • Mismatch negativity (MMN)
  • Novel object recognition e.g. sub-chronic PCP-induced deficit
  • Reversal learning
  • Reversal of amphetamine/PCP-induced behaviours using LABORAS

schizophrenia modelThis list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.